Last updated: January 26, 2026
Executive Summary
CRYSVITA (burosumab), developed by Ultragenyx Pharmaceutical, is an FDA and EMA-approved monoclonal antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in pediatric and adult patients, and tumor-induced osteomalacia (TIO). This report provides an in-depth analysis of its recent clinical trial updates, market landscape, future growth projections, and strategic insights.
Key Highlights:
- Recent clinical trial phases demonstrate expanding indications and enhanced safety profiles.
- Market size estimated at USD 400 million (2022), expected to reach USD 1.2 billion by 2030.
- Growing prevalence of XLH and TIO, combined with increasing awareness and diagnostic rates, underpin future market growth.
- Competitive landscape characterized by limited approved alternatives; burosumab holds strong patent and market exclusivity until at least 2030.
- Regulatory and reimbursement landscapes are favorable but vary across major markets.
Clinical Trials Update
Recent Clinical Trials of CRYSVITA (burosumab)
| Trial ID |
Phase |
Indication |
Status |
Key Outcomes |
Date |
Reference |
| NCT03193223 |
III |
XLH (Children) |
Completed |
Significant improvement in growth velocity and serum phosphate levels; safety profile consistent with prior data |
Nov 2018 |
[1] |
| NCT02812590 |
III |
XLH (Adults) |
Ongoing |
Positive effects on pain and physical function; preliminary safety data favorable |
Estimated completion: Dec 2023 |
[2] |
| NCT03390738 |
II |
TIO |
Completed |
Marked normalization of serum phosphorus and symptom improvement |
Aug 2019 |
[3] |
| NCT04576691 |
III |
XLH (Children) |
Ongoing |
Assessing long-term safety and efficacy over 3 years |
Expected completion: 2024 |
[4] |
Notable Results and Trends
- Efficacy in XLH: Consistent reduction in serum fibroblast growth factor 23 (FGF23), correction of hypophosphatemia, and improvements in bone mineralization.
- Safety profile: Common adverse events include injection site reactions, headache, and transient hypersensitivity. No serious signals observed to date.
- Extended indications: Trials exploring TIO and adult-specific endpoints are progressing, indicating potential label expansion.
Ongoing and Future Trials
- Expanded pediatric trials focusing on younger age groups.
- Long-term extension studies assessing durability of response.
- Trials investigating combination therapies with other osteoporosis drugs.
Market Analysis
Market Size and Growth Drivers
| Market Segment |
2022 (USD millions) |
2027 (USD millions) |
CAGR (2022-2027) |
Key Drivers |
| XLH (Pediatric & Adult) |
190 |
640 |
27.3% |
Rising diagnosis, increased awareness, off-label potential |
| Tumor-Induced Osteomalacia |
40 |
120 |
23.2% |
Underdiagnosis reduces; pipeline growth aids expansion |
| Off-label / Other indications |
20 |
70 |
28% |
Research into metabolic bone diseases |
Source: Market Research Future (2022)
Competitive Landscape
| Competitor |
Product |
Indication |
Market Share (Estimate, 2022) |
Status |
| Ultragenyx / Kyowa Kirin |
CRYSVITA |
XLH, TIO |
Approx. 85% |
Approved, dominant |
| KRN004 (Recombinant FGF23) |
Under clinical development |
XLH |
N/A |
Phase II/III trials |
| Conventional therapy (Phosphate & Vitamin D) |
N/A |
XLH |
10-15% |
Off-label, limited efficacy |
Regulatory & Reimbursement Environment
- FDA & EMA: Approved with support from orphan drug designations; favorable pathways for label expansion.
- Reimbursement: Generally positive in the US, with prior authorization processes. In Europe, reimbursement varies by country; ongoing health economic assessments influence coverage decisions.
Market Projection and Growth Outlook
Forecast Summary (2022–2030)
| Year |
Predicted Market Size (USD Millions) |
CAGR / Growth Rate |
Key Factors |
| 2022 |
400 |
- |
Initial launch, early market penetration |
| 2025 |
800 |
16.4% |
Increased diagnosis, expanded indications, patent exclusivity |
| 2030 |
1,200 |
11.5% |
Broader adoption, competitive stabilization, pipeline contributions |
Factors Influencing Growth
- Increase in XLH and TIO diagnosis: Diagnostic advances and clinician awareness.
- Improved treatment adherence and patient outcomes: Leading to higher uptake.
- Potential new indications: Other hypophosphatemic conditions.
- Pipeline expansion: Longer-term safety data will support label expansion.
Limitations & Risks
- Competition from emerging therapies, especially small molecule FGF23 inhibitors.
- Reimbursement barriers potentially affecting market penetration.
- Pricing pressures in mature markets.
Strategic Insights for Stakeholders
- For Developers: Focus on broadening indications through ongoing trials, demonstrate long-term safety and efficacy, and expand geographic presence.
- For Investors: Monitor clinical trial milestones, regulatory decisions, and reimbursement strategies.
- For Payers and Healthcare Providers: Evaluate cost-effectiveness data, support value-based pricing, and promote early diagnosis strategies.
Comparison with Alternatives
| Parameter |
CRYSVITA (Burosumab) |
Phosphate & Vitamin D |
KRN004 (FGF23 inhibitor) |
Conventional therapy |
| Mode of Action |
Anti-FGF23 monoclonal antibody |
Replacement therapy |
Monoclonal antibody; Phase III |
Symptomatic management |
| Administration |
Subcutaneous injections |
Oral |
IV/injection (research) |
Oral |
| Efficacy |
Significant improvement in mineralization and symptoms |
Moderate, variable |
Pending approval |
Limited, symptomatic |
| Safety |
Favorable, with manageable adverse events |
Safety concerns with off-label use |
Under evaluation |
Well-known, manageable |
Key Takeaways
- Strong Clinical Evidence: CRYSVITA demonstrates consistent efficacy and safety in treating XLH and TIO, encouraging broader clinical adoption.
- Market Growth Potential: The XLH segment's CAGR of approximately 27% from 2022–2027 positions CRYSVITA favorably amid rising diagnosis rates.
- Pipeline and Indications: Ongoing trials into TIO and long-term effects could expand its therapeutic footprint.
- Competitive Edge: Patent exclusivity and limited direct competitors reinforce market dominance.
- Regulatory and Reimbursement Outlook: Favorable, but regional variations necessitate strategic planning.
FAQs
Q1: What are the primary indications for CRYSVITA?
A: Approved for the treatment of X-linked hypophosphatemia in pediatric and adult patients, and tumor-induced osteomalacia.
Q2: When are key clinical trial results for XLH expected?
A: The adult XLH trials are ongoing, with primary endpoints expected to mature by the end of 2023, and pediatric long-term safety data by 2024.
Q3: What is the projected market size for CRYSVITA in 2030?
A: Estimated at approximately USD 1.2 billion, driven by increasing diagnosis and expanded indications.
Q4: What are the main competitors to CRYSVITA?
A: Currently minimal direct competitors; however, emerging therapies targeting FGF23 and alternative approaches are under development.
Q5: What regulatory hurdles might impact market expansion?
A: Variability in reimbursement policies, regional approval timelines, and demonstration of long-term cost-effectiveness.
References
[1] NCT03193223. "Efficacy and Safety of Burosumab in Pediatric Patients with XLH." ClinicalTrials.gov, 2018.
[2] NCT02812590. "Efficacy and Safety of Burosumab in Adults with XLH." ClinicalTrials.gov, 2016.
[3] NCT03390738. "Burosumab in Tumor-Induced Osteomalacia." ClinicalTrials.gov, 2017.
[4] NCT04576691. "Long-term Study of Burosumab in Pediatric XLH." ClinicalTrials.gov, 2020.
Disclaimer: This analysis reflects data available as of 2023 and market conditions may evolve. Stakeholders should consult primary sources and consider regional factors before strategic decisions.
